Insights & Resources – COD Research

Medical Affairs

CT Quality Assurance

Clinical Services

Biometrics

Transforming Complexity into Success: A Large-Scale Global Phase III Biosimilar Dermatology Trial

Strategic Planning for Patient Recruitment

Pulmonary Disease Introduction: Prevalence, Causes, Prevention & Treatment

EMA
FDA
MHRA

PSUSA/00002774/202408
Source: EMA Published on 2025-04-16
PSUSA/00000027/202407
Source: EMA Published on 2025-04-16
Human medicines European public assessment report (EPAR): Dyrupeg, pegfilgrastim, Date of authorisation: 28/03/2025, Status: Authorised
Source: EMA Published on 2025-04-16
Human medicines European public assessment report (EPAR): Scemblix, asciminib, Date of authorisation: 25/08/2022, Revision: 9, Status: Authorised
Source: EMA Published on 2025-04-16
Human medicines European public assessment report (EPAR): Zerbaxa, ceftolozane,tazobactam, Date of authorisation: 18/09/2015, Revision: 16, Status: Authorised
Source: EMA Published on 2025-04-16
Human medicines European public assessment report (EPAR): Plavix, clopidogrel, Date of authorisation: 15/07/1998, Revision: 52, Status: Authorised
Source: EMA Published on 2025-04-16

Read More